Latest Prostate cancer Stories
Prostate-Only Radiation Therapy Centers throughout the United States Consistently Demonstrate the Highest Clinical Quality LAWRENCEVILLE, N.J., April 18, 2013 /PRNewswire-iReach/ -- The Premier Prostate Cancer Center, a partnership between AKSM/Oncology and the Urology Care Alliance (UCA), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology. The American College of Radiology...
Multispectral photoacoustic imaging, which combines laser optics and ultrasound imaging technologies, can reliably distinguish between benign and malignant prostate tissue, a new study indicates. Researchers at the University of Rochester looked at 42 prostatectomy specimens using the new imaging technique. Multispectral photoacoustic imaging, still in its infancy, predicted 25 out of 26 benign tissues correctly and 13 out of 16 malignant tissues correctly, said Dr. Vikram Dogra, lead...
TIRAT CARMEL, Israel, April 18, 2013 /PRNewswire/ -- InSightec Ltd. announced today that the US Centers for Medicare & Medicaid Services (CMS), a federal agency within the US Department of Health and Human Services (HHS), has created a new billing code for MR guided focused ultrasound treatment of pain palliation of metastatic bone lesions and has established a Medicare payment rate for hospital outpatient departments. InSightec's ExAblate received Food and Drug...
Newly released brachytherapy delivery process features logical workflow and intuitive system operation for greater user and patient safety NEW ORLEANS, April 18, 2013 /PRNewswire/ -- At the 2013 American Brachytherapy Society (ABS) meeting April 18-20 in New Orleans, Nucletron, an Elekta company, (booth #300), will introduce its newly redesigned Flexitron® remote afterloading platform. Flexitron emphasizes safety and efficiency in the brachytherapy workflow, increasing the...
Unprecedented Results Compared With Current Standard of Care BETHESDA, Md., April 18, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that Brad Silver, an All American swimming and water polo athlete who was diagnosed with Glioblastoma multiforme (GBM) brain cancer in late 2002, and was treated with DCVax-L in March of 2003, just celebrated the...
Program Builds Prostate Cancer Awareness and Action in Support of America's Veterans and Adds to Other Janssen Biotech Education Efforts for Men at High Risk, including Making Awareness a Priority (M.A.P.) HORSHAM, Pa., April 18, 2013 /PRNewswire/ -- Legendary NASCAR(® )driver, team owner, and prostate cancer survivor Richard Petty has teamed with Janssen Biotech, Inc. on Show Your Stripes for Prostate Cancer Awareness. This new educational initiative raises awareness about...
26-second moment of silence will be observed, runners encouraged to wear blue and yellow DALLAS, April 17, 2013 /PRNewswire-USNewswire/ -- The 3rd Annual Your Next Step is the Cure 5K walk/run at Reverchon Park on Saturday will honor the victims and heroes of Monday's Boston Marathon bombing by starting with a 26-second moment of silence - one second for every mile of the marathon. The Bonnie J. Addario Lung Cancer Foundation (LCF), who hosts the event to raise funds for lung cancer...
A new design of screening could improve ratio between benefit and harms of screening Focusing prostate cancer testing on men at highest risk of developing the disease is likely to improve the ratio between benefits and the harms of screening, suggests a paper published today on bmj.com. Prostate specific antigen (PSA) screening is widely used for the early detection of prostate cancer, but remains highly controversial, as it became widespread long before evidence to prove its value....
Polaris Scientific Colleagues from Several University Cancer Centers Present Data at 2013 AACR Meeting in Washington, DC SAN DIEGO, April 17, 2013 /PRNewswire/ -- Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if...
Findings of CALGB 9581 Published in the Journal of Clinical Oncology Support Expansion of Colon Cancer Reimbursement and Broader Patient Access REDWOOD CITY, Calif., April 17, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology (JCO) published positive results from the large CALGB 9581 clinical validation study of the Oncotype DX® colon cancer test in stage II colon cancer patients. The findings provide further...
